Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
- Status
- COMPLETED
- Phase
- PHASE3
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
- Status
- UNKNOWN
- Phase
- PHASE2
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- Status
- RECRUITING
- Phase
- NA
Tw HER2 Positive Breast Cancer Productivity & Utility Study
- Status
- UNKNOWN
- Phase
- N/A
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
- Status
- UNKNOWN
- Phase
- PHASE2
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
- Status
- UNKNOWN
- Phase
- PHASE2